Clinicopathological characteristics, diagnosis and treatment of melanoma in Serbia: The Melanoma Focus Study | Zendy

Lidija Kandolf Sekulović | Zendy; Nada Babović | Zendy; M. Balic | Zendy; Borislava Nikolin | Zendy; Dejan Nikolić | Zendy; Zlata Janjić | Zendy; Neven Jokic | Zendy; Željko Mijušković | Zendy; Milica Rajović | Zendy; Marijan Novaković | Zendy; Svetislav Vrbić | Zendy; Ivica Pejcic | Zendy; Predrag Kovačević | Zendy; Dragan Mihajlović | Zendy; Tatjana Roganović | Zendy; Ferenc Vicko | Zendy; Jeleikolić | Zendy; Marija Marinković | Zendy; Zorana Bizetic | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinicopathological characteristics, diagnosis and treatment of melanoma in Serbia: The Melanoma Focus Study

Author(s) -

Lidija Kandolf Sekulović,

Nada Babović,

M. Balic,

Borislava Nikolin,

Dejan Nikolić,

Zlata Janjić,

Neven Jokic,

Željko Mijušković,

Milica Rajović,

Marijan Novaković,

Svetislav Vrbić,

Ivica Pejcic,

Predrag Kovačević,

Dragan Mihajlović,

Tatjana Roganović,

Ferenc Vicko,

Jeleikolić,

Marija Marinković,

Zorana Bizetic

Publication year - 2014

Publication title -

vojnosanitetski pregled

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.123

H-Index - 19

eISSN - 2406-0720

pISSN - 0042-8450

DOI - 10.2298/vsp131014052k

Subject(s) - medicine , dacarbazine , melanoma , stage (stratigraphy) , oncology , dermatology , disease , nodular melanoma , lymph node , metastatic melanoma , chemotherapy , surgery , cancer , cancer research , paleontology , biology

Treatment options for metastatic melanoma in Serbia are limited due to the lack of newly approved biologic agents and the lack of clinical studies. Also, there is a paucity of data regarding the treatment approaches in different tertiary centers and efficacy of available chemotherapy protocols. The aim of this study was to obtain more detailed data about treatment protocols in Serbia based on structured survey in tertiary oncology centers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research